直接面向消费者的生育力检测:生育患者与生殖内分泌医生的使用情况及感知效用
研究调查了2020年12月至2021年12月期间就诊于杜克生育中心的非孕患者及生殖内分泌与不孕症学会成员,比较患者与生殖内分泌医生对直接面向消费者的生育力检测的使用情况和推荐可能性。共425例患者和178名医生完成调查,患者对排卵预测方法使用普遍,医生对多数检测的效用评分显著低于患者,仅尿排卵预测评分显著高于患者。
要点
- 患者使用日历法预测排卵83.8%,尿排卵预测78.8%,基础体温监测30.8%。
- 生殖内分泌医生对多数直接面向消费者的生育力检测效用评分较患者平均低4.2分(P<0.001)。
- 仅尿排卵预测医生评分较患者高1.0分(P<0.001)。
核心结论
- 排卵预测方法在生育患者中常用,患者与生殖内分泌医生对直接面向消费者的生育力检测的感知效用存在显著不一致,需要患者教育和指南来更好地指导考虑此类检测的个体。
研究设计与样本
- 2020年12月至2021年12月期间向就诊于杜克生育中心的非孕患者发送电子邀请参与患者调查,同时向生殖内分泌与不孕症学会成员发送电子邮件邀请参与医生调查。
- 直接面向消费者的生育力检测定义为非医生开具或非医生办公室进行的检测,包括日历法预测排卵、尿排卵预测试剂盒、基础体温监测、激素分析、卵巢储备检测和精液分析。
- 患者和医生被问及推荐某种直接面向消费者的生育力检测的可能性,采用0-10分李克特量表。
- 共425例患者(应答率50.5%)和178名生殖内分泌医生(应答率21.4%)完成调查。
主要发现
- 患者报告使用日历法预测排卵83.8%、尿排卵预测78.8%、基础体温监测30.8%、激素分析15.3%、精液分析10.1%、卵巢储备检测9.2%。
- 生殖内分泌医生对所有直接面向消费者的生育力检测的效用评分显著低于患者(平均不一致-4.2,P<0.001),但尿排卵预测除外,医生评分显著更高(不一致+1.0,P<0.001)。
- 患者中既往妊娠与家庭排卵预测使用显著相关(调整比值比3.21,95%置信区间1.2-9.83)。
临床怎么用
- 原文结论指出需要患者教育和指南来更好地指导考虑直接面向消费者的生育力检测的个体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What is the utilization of direct-to-consumer fertility tests (DTCFT) among fertility patients? How does the perceived utility of DTCFT differ between patients and reproductive endocrinologists (REI)? DESIGN: Infertility patients visiting the Duke Fertility Center between December 2020 and December 2021 were sent an electronic invitation to participate in a patient survey. Members of the Society of Reproductive Endocrinology and Infertility were also sent e-mail invitations to participate in the REI survey. DTCFT were defined as tests not ordered by a physician or performed at a physician's office, including calendar methods of ovulation prediction, urinary ovulation prediction kits, basal body temperature (BBT) monitoring, hormone analysis, ovarian reserve testing and semen analysis. Patients and REI were asked how likely they were to recommend a given DTCFT, on a 0-10 Likert scale. RESULTS: In total, 425 patients (response rate 50.5%) and 178 REI (response rate 21.4%) completed the surveys. Patients reported the utilization of calendar methods of ovulation prediction (83.8%), urinary ovulation prediction (78.8%), BBT monitoring (30.8%), hormone analysis (15.3%), semen analysis (10.1%) and ovarian reserve testing (9.2%). REI rated the utility of all DTCFT significantly lower than patients did (average discordance -4.2, P < 0.001), except for urinary ovulation prediction, which REI gave a significantly higher score (discordance +1.0, P < 0.001). Prior pregnancy was significantly associated with home ovulation prediction utilization among patients (adjusted odds ratio 3.21, 95% confidence interval 1.2-9.83). CONCLUSIONS: Methods of ovulation prediction are commonly used by fertility patients. Significant discordance exists in the perceived utility of DTCFT between patients and REI. Patient education and guidelines are needed to better inform individuals considering DTCFT.
引用
- Peipert BJ, Harris BS, Selter JH, et al. Direct-to-consumer fertility testing: utilization and perceived utility among fertility patients and reproductive endocrinologists. Reprod Biomed Online. 2022. PMID: 36610890. doi:10.1016/j.rbmo.2022.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。